NAWAL Salama GOUDA

Prof. Dr. NAWAL Salama GOUDA

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
ETEman Toraih
Eman Toraih
AEAlia Ellawindy
Alia Ellawindy
SFSalma Y. Fala
Salma Y. Fala
EAEssam Al Ageeli
Essam Al Ageeli
NAWAL Salama GOUDANAWAL Salama GOUDA
NAWAL Salama GOUDA
SHSomaya Hosny
Somaya Hosny

1 May 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
NAWAL Salama GOUDANAWAL Salama GOUDA
NAWAL Salama GOUDA
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy
ETEman Toraih
Eman Toraih
Background: Cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) is one of the essential brakes expressed on T cells that prevent T‐cell hyperactivation‐associated autoimmune disorders. Several CTLA4 polymorphisms were implicated in the regulation of gene expression. We aimed to explore the association of CTLA4 expression and rs231775 (c.49A>G) variant with vitiligo risk and severity of the disease in a sample of the Middle Eastern population.Methods: The CTLA4 gene expression and genotyping for rs231775 (A/G) variant were assessed in 161 vitiligo patients and 165 controls using a real‐time polymerase chain reaction. Vitiligo Area Severity Index (VASI) and Vitiligo Disease Activity score (VIDA) were evaluated.Results: A higher frequency of rs231775 G allele was observed in vitiligo cases than controls (45% vs. 33%, p = 0.002). After adjustment of age, sex, family history of vitiligo, and CTLA expression level, using multivariate analysis, G/G carriers were associated with a higher risk of vitiligo under recessive (OR = 2.94, 95% CI = 1.61–5.35, p < 0.001), dominant (OR = 1.87, 95% CI = 1.14–3.06, p = 0.013), and homozygote comparison (OR = 3.34, 95% CI = 1.73–6.42, p = 0.001) models. Although the CTLA4 relative expression levels were comparable to that of controls, G/G carriers exhibited a significantly lower expression profile (median = 0.63, IQR = 0.34–1.75) than A/A (median = 1.43, IQR = 0.39–4.25, p = 0.018) and A/G carriers (median = 1.68, IQR = 0.49–3.92, p = 0.007). No significant associations of CTLA4 variant/expression with disease severity and/or activity were observed.Conclusion: The CTLA4 rs231775 variant was associated with vitiligo susceptibility and gene expression; the risky genotype (GG) was associated with lower CTLA4 relative expression levels than the other genotypes. Further large‐scale studies in different populations are warranted.

27 August 2020 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
AAAbdelhady R. Abdel‐Gawad
Abdelhady R. Abdel‐Gawad
SSSameerah Yasain Shaheen
Sameerah Yasain Shaheen
NBNouf Babteen
Nouf Babteen
ETEman Toraih
Eman Toraih
Rami ElshazliRami Elshazli
Rami Elshazli
NAWAL Salama GOUDANAWAL Salama GOUDA
NAWAL Salama GOUDA
Objective: MicroRNAs are large family clusters of small noncoding RNAs that implicated in genetic and epigenetic regulation of several immunological processes and pathways. As an epigenetic modifier, the microRNA 17‐92 cluster host gene (MIR17HG) has been shown to regulate the expression of genes involved in systemic lupus erythematosus (SLE) pathway. This study aimed to explore the association of MIR17HG (rs4284505; A>G) variant with SLE development and phenotype in a sample of the Eastern Mediterranean population.Methods: A total of 326 participants (163 patients with SLE and 163 healthy controls) were enrolled in this study. The different genotypes of the MIR17HG (rs4284505) variant were characterized using the TaqMan real‐time polymerase chain reaction technique. Association with the available clinical and laboratory data, including the systemic lupus erythematosus disease activity index (SLEDAI), was also executed.Results: The MIR17HG (rs4284505)variant showed a protective effect against developing SLE under heterozygote (A/G vs A/A; odds ratio [OR] = 0.10, 95% confidence interval [CI] = 0.05‐0.20,P < 0.001) and dominant (A/G+G/G vs A/A; OR = 0.39, 95% CI = 0.25‐0.61,P < .001) models. This association was consistent even after SLE stratified by lupus nephritis. In contrast, rs4284505 (G/G) genotype conferred increased susceptibility to SLE (G/G vs A/A+A/G; OR = 2.15, 95% CI = 1.31‐3.53,P = .002). Moreover, the rs4284505 variant showed a statistically significant association with mucocutaneous lesions and SLEDAI scores (allP < .05).Conclusion: This study is the first one to explore that the MIR17HG rs4284505 is associated with SLE risk; (A/G) genotype conferred a protective effect, while the (G/G) genotype showed increased susceptibility to SLE and association with the disease severity in the study population.

10 September 2016 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
AAAhmed Abdel-Razik
Ahmed Abdel-Razik
NMNasser Mousa
Nasser Mousa
HEHatem Elalfy
Hatem Elalfy
TSTarek Fouad Sheta
Tarek Fouad Sheta
MAMahmoud Awad
Mahmoud Awad
WEWaleed Eldars
Waleed Eldars

19 April 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
SMShymaa Maher
Shymaa Maher
NINader Ali Ismail
Nader Ali Ismail
ETEman Toraih
Eman Toraih
AHAlaa H. Habib
Alaa H. Habib
NAWAL Salama GOUDANAWAL Salama GOUDA
NAWAL Salama GOUDA
GHGhada M. Helal
Ghada M. Helal
Alopecia areata (AA) is a type of immune-mediated alopecia. Recent studies have suggested microRNAs’ (miRNAs) implication in several cellular processes, including epidermal and hair follicle biology. Single nucleotide polymorphisms (SNPs) can modify gene expression levels, which may induce an autoimmune response. This case–control study included 480 participants (240 for each case/control group). MicroRNA-34a gene (MIR-34A) rs2666433A/G variant was genotyped using real-time allelic discrimination polymerase chain reaction (PCR). Additionally, circulatory miR-34a levels were quantified by quantitative reverse transcription PCR (qRT-PCR). On comparing between alopecia and non-alopecia cohorts, a higher frequency of A variant was noted among patients when compared to controls—A allele: 28 versus 18% (p < 0.001); A/A genotype: 9 versus 2%; A/G genotype: 39 versus 32% (p < 0.001). A/A and A/G carriers were more likely to develop alopecia under heterozygote comparison (OR = 1.83, 95% CI = 1.14–2.93), homozygote comparison (OR = 4.19, 95% CI = 1.33–13.1), dominant (OR = 2.0, 95% CI = 1.27–3.15), recessive (OR = 3.36, 95% CI = 1.08–10.48), over-dominant (OR = 1.65, 95% CI = 1.04–32.63), and log additive (OR = 1.91, 95% CI = 1.3–2.82) models. Serum miR-34a expression levels were upregulated in alopecia patients with a median and quartile fold change of 27.3 (1.42–2430). Significantly higher levels were more pronounced in A/A genotype patients (p < 0.01). Patients carrying the heterozygote genotype (rs2666433 * A/G) were two times more likely to develop more severe disease grades. Stratified analysis by sex revealed the same results. A high expression level was associated with concomitant autoimmune comorbidities (p = 0.001), in particular SLE (p = 0.007) and vitiligo (p = 0.049). In conclusion, the MIR34A rs2666433 (A/G) variant is associated with AA risk and severity in the studied population. Furthermore, high miR-34a circulatory levels could play a role in disease pathogenesis.

17 February 2020 in African Journal of Clinical and Experimental Microbiology
Verified
Journal Article
Open access
PDF file
SES.M. El-Ageery
S.M. El-Ageery
NAWAL Salama GOUDANAWAL Salama GOUDA
NAWAL Salama GOUDA
IFI.M. Fawzy
I.M. Fawzy
ABA. Bahy-Eldeen
A. Bahy-Eldeen
RMR. Mahmoud
R. Mahmoud
Background: Studies have reported relationship between chronic Helicobacter pylori infection and coronary artery disease (CAD). The cytotoxin-associated gene A product (CagA) is an immunodominant protein which indicates infection with virulent H. pylori strains. Significant associations of CagA-positive H. pylori strains with coronary artery disorders have been widely reported. H. pylori is also known to produce different heat shock proteins (HSPs) which can stimulate the production of specific antibody against microbial proteins and capable of eliciting autoimmune reaction against human tissue expressing HSPs such as vascular endothelial cells. The objectives of this study are to investigate the association between H. pylori and CagA with coronary atherosclerosis and CAD, and to determine the possible role of H. pylori HSP60 protein in increasing the risk of CAD development. Methods: This study included 70 patients with stable angina and 70 age and gender-matched controls. Each group was evaluated by clinical history, physical examination, cardiac echocardiography (ECHO) and electrocardiography (ECG) with and without exercise. Fasting blood glucose, total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides (TG) were estimated by automated enzymatic methods. H. pylori IgG, CagA IgG and HSP60 IgG were measured by enzyme-linked immunosorbent assay (ELISA) for both groups. Results: The seroprevalence of H. pylori infection was high in both groups; 75.7% in case and 68.6% in control (p=0.346). Serum IgG levels were significantly higher for CagA (p=0.028) and HSP60 (p<0.001) in cases than in controls. There was significant association between H. pylori and CagA IgGs in cases (p=0.007) but no association in controls (p=0.700). Higher HSP60 IgG level was significantly associated with both positive H. pylori IgG (p<0.001) and CagA IgG (p<0.001) in cases but no significant association was found with H. pylori (p=0.815) or CagA (p=0.332) IgG levels in the control group. Serum values were significantly higher for TC (p<0.001), TG (p<0.001) and LDL (p=0.004) while value for HDL was significantly lower (p<0.001) in H. pylori IgG-positive subjects (case and control). Conclusion: There is serological evidence that H. pylori infection may pose a significant risk factor for CAD. Since H. pylori can be eliminated by specific treatment, this may be a good preventive approach for CAD.Key words: H. pylori, coronary artery disease, CagA, HSP60, serology.